Why include both Tesamorelin and CJC-1295?

Both are GHRH analogs that act on the same pituitary receptor; researchers include Tesamorelin specifically for its well-documented visceral-fat-reducing activity, while CJC-1295 contributes additional GH pulse amplitude.

Is this considered a strong blend?

Yes, in research contexts this triple combination is regarded as one of the more potent GH secretagogue stacks because it engages two GHRH inputs plus a selective ghrelin agonist.

← All peptides

Growth Hormone Secretagogues

Weight & Metabolic

Research Chemical

Tesamorelin / CJC-1295 / Ipamorelin Blend

Also known as: Tesamorelin & CJC-1295 & Ipamorelin, Tesamorelin, CJC-1295 (No DAC), Ipamorelin

A potent three-part research blend pairing two GHRH analogs, Tesamorelin and CJC-1295 (No DAC), with the selective ghrelin agonist Ipamorelin. It is studied for strong synergistic GH release and visceral fat reduction.

Mechanism of Action

Tesamorelin is a stabilized GHRH analog clinically shown to reduce visceral adipose tissue, while CJC-1295 (No DAC, modified GRF 1-29) is another GHRH-receptor agonist that amplifies GH pulse amplitude. Both act on the pituitary GHRH receptor, and Ipamorelin adds a complementary pulse through selective GHS-R1a (ghrelin) receptor activation with minimal cortisol or prolactin effect. The combination drives a strong synergistic increase in pulsatile GH and downstream IGF-1, with Tesamorelin contributing notable lipolytic and visceral-fat-reducing activity.

Half-life: Mixed: Tesamorelin ~26-38 minutes, CJC-1295 (No DAC) ~30 minutes, Ipamorelin ~2 hours
Administration Routes: subcutaneous
Research Status: Research Chemical